About Biocardia Inc
BioCardia (NASDAQ:BCDA) is a pioneering company in the development of regenerative biologic therapies to treat cardiovascular diseases, focusing primarily on heart failure and acute myocardial infarction. Their innovative approach includes a portfolio of cell therapy products and the Helix Biotherapeutic Delivery System, designed for precision delivery of biologics directly to the heart. A key objective for BioCardia is advancing their clinical programs, notably the CardiAMP and CardiALLO cell therapy trials, which aim to improve patient outcomes and redefine the standard of care in cardiovascular medicine. Through rigorous research and development, BioCardia strives to unlock the potential of regenerative medicine for cardiac patients worldwide, demonstrating a commitment to pushing the boundaries of medical science for better health outcomes.
Snapshot
Operations
Products and/or services of Biocardia Inc
- Helical Infusion System for targeted delivery of biotherapeutic agents directly into the heart muscle.
- CardiAMP Cell Therapy System utilizes a patient’s own cells to treat heart failure and ischemic heart diseases.
- Helix Biotherapeutic Delivery System designed for precise, minimally invasive delivery of biologics to cardiac tissue.
- CardiALLO Cell Therapy System is an allogeneic, off-the-shelf stem cell therapy aimed at treating heart diseases.
- Biotherapeutic programs focused on the development of novel treatments for cardiovascular diseases.
- Clinical trial management and support services, offering expertise in the conduct of heart disease-focused clinical studies.
Biocardia Inc executive team
- Dr. Peter A. Altman Ph.D.CEO, President & Director
- Mr. David McClungChief Financial Officer
- Mr. Edward M. GillisSenior Vice President of Devices
- Ms. Miranda Peto BenvenutiInvestor Relations Executive